MAYA AJI: Open Payments
NPI 1841904364 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,373 in 91 payments from 21 companies in 2025. Trend: 2023 $1,124 · 2024 $2,083 · 2025 $2,373
Food & beverage: $2,373
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $417 |
| GlaxoSmithKline, LLC. | 19 | $325 |
| GENZYME CORPORATION | 9 | $274 |
| AOP Health US, LLC | 1 | $272 |
| Lilly USA, LLC | 3 | $147 |
| Viatris Specialty LLC | 7 | $147 |
| Merck Sharp & Dohme LLC | 4 | $103 |
| Grifols USA, LLC | 4 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| Baxter Healthcare | 4 | $94 |
Products named: DUPIXENT, Rapiblyk, FASENRA, TRELEGY ELLIPTA, ZEPBOUND, YUPELRI, ZERBAXA, Prolastin-C Liquid.
Industry payments across TX — which companies pay providers there.
